Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase 3, Open-Label, 52-Week Extension Study

Authors

Institutions

Publication Details

Journal
Neurology and Therapy
Published
2026-03-11
DOI
https://doi.org/10.1007/s40120-026-00905-3
Primary Topic
Migraine and Headache Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase 3, Open-Label, 52-Week Extension Study

Gina Ahmadyar, Shigeya Tanaka, Giovanna Forero, Yasuhiko Matsumori et al.
Neurology and Therapy
Migraine and Headache Studies
article

Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase 3, Open-Label, 52-Week Extension Study

Gina Ahmadyar, Shigeya Tanaka, Giovanna Forero, Yasuhiko Matsumori, Toshimasa Yamamoto, Krisztian Nagy, Jia Bao, Takao Takeshima, Akihiro Takahashi, Rosa de Abreu Ferreira, Hua Guo
article en

Abstract

No abstract available for this paper.
Neurology and Therapy
AbbVie (United States) (US), Kagoshima Prefectural College (JP), Tominaga hospital (JP), Sapporo Science Center (JP), Saitama Medical University (JP)
Openalex Percentile: Top 33%
Migraine and Headache Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.